secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001193125-26-001492
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health outlines 2026 milestones for Revita and Rejuva; cash $85.6M
--------------------------------------------------------------------------

- Preliminary unaudited cash $81.5M at Dec 31, 2025; plus $4.1M from Tranche A warrant exercises on Jan 2, 2026 gives $85.6M.
- Revita: 6-month randomized REMAIN-1 Midpoint data due late Jan 2026; potential PMA filing in H2 2026.
- Rejuva: RJVA-001 first-in-human dosing expected in H2 2026 subject to CTA authorization; regulatory feedback in Q2 2026.
- Cash runway projected through early 2027 to fund all planned 2026 clinical and regulatory milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526001492/0001193125-26-001492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526001492/guts-20260105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-001492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer